Post

Unpopular opinion but if you're interested in the effects of a medical product, it's 'RCT or bust' for me. I can see the case for observational analyses when randomization isn't possible, ethical, or the condition is too rare or some other such thing, but there's no such excuse here.

Saloni@scientificdiscovery.dev

Worth noting that many (not all) of the observational studies so far have been funded by GSK, which sells the shingles vaccine. Vaccines are great and the shingles vaccine is also great (for shingles), but people have got to be a little more skeptical of observational studies funded by pharma IMHO.

Placebo doesn't mean withholding the treatment, but they wouldn't get it as part of the trial. In this case, unlike for many other medical products like drugs, it's possible for people to get vaccines through another route and are similar to OTC. (Plus not as fraught as vaccines for fatal diseases)

and maybe I am misunderstanding--they ARE using the natural experiment that some folks do not get the vaccine, through choice, lack of access, or simply didn't get around to it. Is your worry that there is a variable that correlates with lack of choosing to get this vaccine?

I think observational studies make many more assumptions than RCTs do, and it's harder to tell what can potentially cause issues. Generally, for observational studies on the effects of medicines and vaccines, differential selection into treatment is an important one.

0 reposts1 like

Another that George Davey Smith mentions in the talk is that those who aren't vaccinated and catch shingles have more contact with GPs and are therefore more likely to be diagnosed with dementia (or other conditions), an effect that's seen with other treatments & vaccines at those ages as well.